Valneva SE (VALN) Operating Expenses (2021 - 2026)
Valneva SE (VALN) posted Operating Expenses of -$22.5 million for Q1 2026, down 108.93% sequentially from $251.6 million in Q4 2025, and down 8.29% YoY from -$24.5 million in Q1 2025.
Analysis
Valneva SE (VALN) Operating Expenses (2021 - 2026) Analysis & Trends
Valneva SE has reported Operating Expenses for 6 years, with the latest figure at -$22.5 million in Q1 2026.
- Quarterly Operating Expenses fell 8.29% year-over-year to -$22.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $163.5 million (up 15.37% YoY) and the FY2025 annual result came in at $162.4 million, up 14.03% from the prior year.
- Operating Expenses eased to -$22.5 million in Q1 2026 per VALN's latest filing, from $251.6 million in the prior quarter.
- Over five years, Operating Expenses peaked at $10.6 billion in Q3 2022 and troughed at -$10.5 billion in Q4 2022.
- A 5-year average of $25.1 million and a median of -$23.9 million in 2023 frame the typical range for Operating Expenses.
- The widest YoY moves for Operating Expenses: up 18399.42% in 2022, down 2591.22% in 2022.
- Over 5 years, Operating Expenses stood at -$10.5 billion in 2022, then soared by 101.92% to $202.7 million in 2023, then increased by 6.51% to $215.9 million in 2024, then climbed by 16.57% to $251.6 million in 2025, then slumped by 108.93% to -$22.5 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered -$22.5 million, $251.6 million, and -$39.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -1.05 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 960.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 505.13 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.21 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.06 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 541.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Valneva SE | 578.54 Mn | 437.28 Mn | 1.86 Mn | -21.84 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -21.84 Mn |
| Mar 31, 2026 | -22.46 Mn |
| Dec 31, 2025 | -33.84 Mn |
| Sep 30, 2025 | -39.25 Mn |
| Jun 30, 2025 | -26.44 Mn |
| Mar 31, 2025 | -20.74 Mn |
| Dec 31, 2024 | -33.95 Mn |
| Sep 30, 2024 | -27.36 Mn |
| Jun 30, 2024 | -26.07 Mn |
| Mar 31, 2024 | -23.14 Mn |
| Dec 31, 2023 | -29.06 Mn |
| Sep 30, 2023 | -27.62 Mn |
| Jun 30, 2023 | -23.97 Mn |
| Mar 31, 2023 | -23.08 Mn |
| Dec 31, 2022 | -10.82 Bn |
| Sep 30, 2022 | 10.63 Bn |
| Jun 30, 2022 | -39.86 Mn |
| Mar 31, 2022 | -25.66 Mn |
| Dec 31, 2021 | -82.36 Mn |
| Sep 30, 2021 | -58.09 Mn |